Can CML patients finally take a drug holiday? new study explores stopping treatment
NCT ID NCT03874858
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 26 times
Summary
This study looked at whether people with chronic myeloid leukemia (CML) who have been on the drug nilotinib for at least 3 years can safely reduce their dose or stop treatment entirely. It involved 124 adults and tested two approaches: first, cutting the nilotinib dose in half for a year, then trying to stop; second, if that failed, using a combination of nilotinib and another drug (asciminib) before trying to stop again. The goal was to see if patients could stay in remission without daily medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Bari, BA, 70124, Italy
-
Novartis Investigative Site
Bologna, BO, 40138, Italy
-
Novartis Investigative Site
Cagliari, CA, 09121, Italy
-
Novartis Investigative Site
Catania, CT, 95123, Italy
-
Novartis Investigative Site
Catanzaro, CZ, 88100, Italy
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Milan, MI, 20122, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Palermo, PA, 90127, Italy
-
Novartis Investigative Site
Palermo, PA, 90146, Italy
-
Novartis Investigative Site
Pescara, PE, 65124, Italy
-
Novartis Investigative Site
Perugia, PG, 06129, Italy
-
Novartis Investigative Site
Pisa, PI, 56126, Italy
-
Novartis Investigative Site
Reggio Emilia, RE, 42123, Italy
-
Novartis Investigative Site
Roma, RM, 00144, Italy
-
Novartis Investigative Site
Roma, RM, 00161, Italy
-
Novartis Investigative Site
Roma, RM, 00168, Italy
-
Novartis Investigative Site
Salerno, SA, 84131, Italy
-
Novartis Investigative Site
Siena, SI, 53100, Italy
-
Novartis Investigative Site
Orbassano, TO, 10043, Italy
-
Novartis Investigative Site
Torino, TO, 10126, Italy
-
Novartis Investigative Site
Torino, TO, 10128, Italy
-
Novartis Investigative Site
Verona, VR, 37134, Italy
-
Novartis Investigative Site
Naples, 80131, Italy
-
Novartis Investigative Site
Novara, 28100, Italy
Conditions
Explore the condition pages connected to this study.